KRAS and colorectal carcinoma: The PICCOLO trial included 460 advanced KRAS wild-type CRC patients that had not been treated previously with EGFR-targeted agents; the PFS in the panitumumab plus irinotecan group was markedly superior to that of the irinotecan group alone, and there was no differentiation in the OS between the two groups, with the combination of irinotecan plus panitumumab not improving the OS in patients with KRAS wild-type tumors (Seymour et al., 2013).